Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Pluristem Therapeutics (PSTI) Share Price
Media headlines about Pluristem Therapeutics (NASDAQ:PSTI) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9817108360668 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:
- Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights (finance.yahoo.com)
- Pluristem Therapeutics, Inc. (PSTI) Announces Earnings Results (americanbankingnews.com)
- Is It Time To Buy Pluristem Therapeutics Inc (PSTI)? (finance.yahoo.com)
- Pluristem Therapeutics, Inc. (PSTI) Short Interest Update (americanbankingnews.com)
Several equities research analysts recently commented on PSTI shares. Seaport Global Securities reiterated a “buy” rating and issued a $5.00 price objective on shares of Pluristem Therapeutics in a research report on Friday, October 6th. Maxim Group restated a “buy” rating and issued a $2.00 target price on shares of Pluristem Therapeutics in a report on Tuesday, September 5th. HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Thursday, August 17th. ValuEngine upgraded shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered shares of Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $4.38.
Pluristem Therapeutics (NASDAQ PSTI) traded down $0.07 during trading hours on Friday, reaching $1.49. 309,979 shares of the company’s stock were exchanged, compared to its average volume of 763,608. Pluristem Therapeutics has a 52 week low of $1.04 and a 52 week high of $2.12.
Pluristem Therapeutics (NASDAQ:PSTI) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.08). equities research analysts predict that Pluristem Therapeutics will post -0.34 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2017/11/19/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-pluristem-therapeutics-psti-share-price.html.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.